New Diabetes Drug Faces a Critical Review Before an F.D.A. Advisory Panel
Monday, July 18, 2011 - 12:40
in Health & Medicine
An F.D.A. advisory committee is set this week to consider whether dapagliflozin can overcome safety concerns and reach the market.
